• ERK Pathway Links IFNγ Signaling to Melanoma Cell Death

  2026-06-03

  Champhekar et al. reveal that ERK activation is a critical mediator of interferon gamma (IFNγ)-induced apoptosis in melanoma, independent of common oncogenic mutations. This discovery refines our understanding of immune signaling in tumor suppression and suggests new avenues for targeting melanoma resistance.

• Plk1 Regulation of p31comet in Mitotic Checkpoint Complex Di

  2026-06-03

  This study elucidates how Polo-like kinase 1 (Plk1) modulates the function of p31comet, a key player in mitotic checkpoint complex (MCC) disassembly. By revealing the phosphorylation-dependent inhibition of p31comet by Plk1, the findings advance understanding of mitotic checkpoint regulation and highlight implications for cell cycle research and targeted cancer studies.

• Super-Enhancer Hijacking of LINC01977 Drives LUAD Progressio

  2026-06-02

  Zhang et al. (2022) reveal that super-enhancer hijacking activates LINC01977, which promotes early-stage lung adenocarcinoma progression via the canonical TGF-β/SMAD3 pathway. This mechanistic insight highlights a new epigenetic vulnerability and suggests potential avenues for transcriptional coactivator inhibition in lung cancer biology research.

• VTA-PBN Dopaminergic Projections Accelerate Propofol Emergen

  2026-06-02

  This study demonstrates that dopaminergic neurons projecting from the ventral tegmental area (VTA) to the parabrachial nucleus (PBN) play a critical role in facilitating emergence from propofol anesthesia in rats. Using targeted chemogenetic and optogenetic approaches, the research provides new insight into neuronal circuits governing anesthetic recovery.

• XAV-939 and the Next Frontier in Wnt/β-Catenin Modulation

  2026-06-01

  This article unpacks the mechanistic and translational significance of XAV-939 (NVP-XAV939) as a tankyrase 1 and 2 inhibitor, offering strategic insights for researchers seeking to control Wnt/β-catenin signaling in cancer, fibrosis, and regenerative medicine. Drawing on recent advances in scalable extracellular vesicle therapies and rigorous in vitro/in vivo workflows, we outline protocol parameters, discuss the clinical landscape, and highlight how APExBIO's XAV-939 enables reproducible, targeted investigation beyond the scope of standard product pages.

• GSK-923295 and CENP-E: Unraveling Mitotic Control for Transl

  2026-06-01

  This thought-leadership article explores the mechanistic role of CENP-E in mitosis, integrating fresh insights from recent centromere research to guide translational scientists in leveraging GSK-923295. By blending protocol guidance, competitive context, and future outlook, the discussion positions APExBIO’s GSK-923295 as a transformative tool for advancing mitosis-targeted cancer research and centromere biology.

• SNS-032 (BMS-387032): Applied CDK Inhibition in Cancer & Vir

  2026-05-31

  SNS-032 (BMS-387032) from APExBIO delivers potent, selective inhibition of CDK2, CDK7, and CDK9, empowering researchers in oncology and emerging host-targeted antiviral studies. Its robust performance in cell cycle and transcriptional workflows, and validated efficacy against tumor and viral egress models, make it a versatile tool for advanced experimental design.

• miR-196a Drives Esophageal Adenocarcinoma via c-Myc/TERT/NFκ

  2026-05-30

  This study uncovers how microRNA-196a accelerates the aggressiveness of esophageal adenocarcinoma by orchestrating the c-Myc/TERT/NFκB signaling axis. The findings highlight new mechanistic links between miR-196a, EMT, and oncogenic signaling, suggesting targeted molecular interventions could mitigate tumor progression.

• AT13387 (SKU A4056): Practical Solutions for Hsp90 Inhibitio

  2026-05-29

  This article delivers a scenario-driven, evidence-based exploration of AT13387 (SKU A4056) for cell viability, proliferation, and cytotoxicity assays in cancer biology research. By addressing real laboratory challenges with quantitative data and protocol insights, researchers gain actionable guidance for leveraging this potent Hsp90 inhibitor. APExBIO's AT13387 is positioned as a reliable resource for reproducible, high-impact workflows.

• Trelagliptin Enhances Osteoblastic Differentiation via RUNX2

  2026-05-29

  This study demonstrates that Trelagliptin, a DPP-4 inhibitor, promotes osteoblastic differentiation and mineralization in MC3T3-E1 cells by upregulating RUNX2 through AMPK signaling. These findings provide a mechanistic basis for potential therapeutic strategies targeting osteoporosis, especially in diabetic patients.

• PP2A-Mediated Autophagy Drives Candida albicans Biofilm Resi

  2026-05-28

  This study elucidates how protein phosphatase 2A (PP2A) regulates drug resistance in Candida albicans biofilms through autophagy-related protein phosphorylation. The findings offer new mechanistic insight relevant to antifungal drug development and strategies targeting biofilm-associated resistance.

• CKI 7 Dihydrochloride: Strategic CK1 Inhibition in Translati

  2026-05-28

  Explore how CKI 7 dihydrochloride advances translational research by selectively inhibiting Casein kinase 1, providing new mechanistic insight and practical guidance for targeting key cancer pathways such as Wnt signaling and circadian rhythm regulation. This thought-leadership article distills mechanistic advances, protocol recommendations, and strategic considerations for leveraging CKI 7 dihydrochloride in high-impact oncology research, with a focus on metastasis control and experimental rigor.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-27

  This study introduces a patient-derived gastric cancer assembloid system that integrates matched tumor organoids with diverse stromal cell subpopulations, providing a physiologically relevant in vitro model. The approach enables nuanced investigation of tumor–stroma interactions, gene expression variability, and drug response heterogeneity, supporting advancements in personalized cancer therapy research.

• Chloroquine Diphosphate (A8628): Reliable Autophagy Modulati

  2026-05-27

  Chloroquine diphosphate (SKU A8628) is a rigorously characterized autophagy modulator and TLR7/TLR9 inhibitor, enabling reproducible cell viability and proliferation assays in cancer research. This article guides scientists through real laboratory scenarios, highlighting the evidence-based advantages and workflow reliability of A8628. Explore practical solutions and protocol insights optimized for sensitivity and consistency.

• Aurora Kinase A Regulates Trained Immunity via SAM Metabolis

  2026-05-26

  Li et al. uncover a novel function of Aurora kinase A in sustaining trained immunity by regulating endogenous S-adenosylmethionine (SAM) metabolism through the mTOR-FOXO3-GNMT axis. This finding connects metabolic and epigenetic control of innate immune memory, providing mechanistic insight relevant to both immunology and cancer research.

15791 records 1/1053 page Next 12345 下5页 Last page